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Email: paola.porcari@ncl.ac.ukNMR Biomed. 2016; 29: 1577–1589Glioma models have provided important insights into human brain cancers. Among the investiga-
tive tools, MRI has allowed their characterization and diagnosis.
In this study, we investigated whether diffusion MRI might be a useful technique for early detec-
tion and characterization of slow‐growing and diffuse infiltrative gliomas, such as the proposed
new models, LN‐2669GS and LN‐2540GS glioma sphere xenografts. Tumours grown in these
models are not visible in conventional T2‐weighted or contrast‐enhanced T1‐weighted MRI at
14.1 T.
Diffusion‐weighted imaging and diffusion tensor imaging protocols were optimized for contrast
by exploring long diffusion times sensitive for probing the microstructural alterations induced
in the normal brain by the slow infiltration of glioma sphere cells.
Compared with T2‐weighted images, tumours were properly identified in their early stage of
growth using diffusion MRI, and confirmed by localized proton MR spectroscopy as well as
immunohistochemistry. The first evidence of tumour presence was revealed for both glioma
sphere xenograft models three months after tumour implantation, while no necrosis, oedema
or haemorrhage were detected either by MRI or by histology. Moreover, different values of dif-
fusion indices, such as mean diffusivity and fractional anisotropy, were obtained in tumours
grown from LN‐2669GS and LN‐2540GS glioma sphere lines. These observations highlighted
diverse tumour microstructures for both xenograft models, which were reflected in histology.
This study demonstrates the ability of diffusion MRI techniques to identify and investigate early
stages of slow‐growing, invasive tumours in the mouse brain, thus providing a potential imaging
biomarker for early detection of tumours in humans.
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MRS1 | INTRODUCTION
Diffuse gliomas (World Health Organization (WHO) Grade II–IV)1 are
the most common primary brain tumours in humans and one of the
leading causes of cancer‐related deaths in adults.2 Their diffuse infiltra-
tion into the surrounding normal brain precludes complete resection
and they all eventually recur, usually having progressed to a more
aggressive tumour. The infiltrative part will give rise to tumour recur-
rence even in MRI‐controlled, macroscopically fully resected patients,
since the extent of invasion is not visible using conventional T1 and
T2‐weighted MRI. Hence, it is difficult to target treatment to thiswileyonlinelibrary.com/journ‘invisible’ part. Among diffuse gliomas, glioblastoma (GBM; WHO
Grade IV) is the most aggressive form,3 with a median overall survival
of only 14.6 months4 despite multimodal treatment of maximal safe
resection, followed by combined chemo‐radiotherapy. Visualization
of the infiltrative portion of gliomas is a necessary first step for testing
novel treatment strategies affecting migrating tumour cells.5
Over the past decades, rodent models of diffuse infiltrative
gliomas have been extensively investigated6–8 to better understand
the genetic and molecular pathology of malignant gliomas and to
assess the efficacy of newer therapies.9 Although none of the existing
models fully reflect the corresponding human neoplasm,7 their use inCopyright © 2016 John Wiley & Sons, Ltd.al/nbm 1577
1578 PORCARI ET AL.combination with advanced neuroimaging techniques10–12 has led to
the identification of imaging biomarkers for the detection of brain can-
cers and early prediction of therapeutic efficacy.13
MRI allows non‐invasive in vivomonitoring of both tumour growth
and response to therapy, and provides detailed structural information
on tumour and brain tissue.14 Morphological features of diffuse glio-
mas, e.g. tumour location and size, necrosis, peritumoral oedema, het-
erogeneity, and haemorrhagic foci, can be determined using routine
contrast‐enhanced T1‐ and T2‐weighted MRI. Nevertheless, conven-
tional MRI has limited sensitivity and specificity in evaluating early
therapeutic effects, in determining histological type and tumour grad-
ing and in accurately delineating tumour extent.15 Contrast‐enhanced
T1‐weighted MRI tends to underestimate the diffuse infiltration of gli-
oma cells16 depending on the blood–brain‐barrier integrity at the infil-
trative margins.17 In addition, histological correlation with T2‐weighted
images of gliomas has shown glioma‐infiltrating cells beyond the
hyper‐intense region on T2‐weighted images.
18
To overcome these limitations, advanced MRI methods sensitive
to tissue properties related to brain cancer biology and glioma cell
migration have been developed and implemented.14,19 Among these,
diffusion MRI,20 which reflects information on the tissue microstruc-
ture, potentially allows imaging of glioma‐infiltrating cells in the normal
brain21 and the detection of early changes in the tumour microenviron-
ment following treatment.22 The diffusion‐weighted MR signal, which
is recorded as a function of diffusion weighting or b value, is affected
by the complex composition and the geometric architecture of the
investigated tissues. Due to the presence of structural barriers, water
diffusion in brain tissue is restricted and/or hindered. Therefore, the
diffusion time (Δ) becomes a key parameter for improving the sensitiv-
ity of diffusion MRI to tissue microstructure. For longer Δ, water mol-
ecules in the brain probe more obstacles and/or barriers over larger
spatial scales, which are, however, smaller than the dimensions of a
pixel. Moreover, with increasing Δ, diffusion can be considered
‘quasi‐Gaussian’ in normal physiological conditions, and the measured
diffusion coefficient shows a rather monotonic behaviour as function
of Δ and membrane permeability,23 which is more visible for shorter
diffusion times.24 Therefore, the measured diffusion coefficient, which
reflects tissue characteristics, might change with the tumour progres-
sion for longer Δ, thus playing an important role in evaluating healthy
and diseased tissues. To our knowledge, no previous studies have
reported the effect of Δ on water diffusion in human glioma models,
except an in vitro study on glioma cells.25 By increasing the diffusion
time, water molecules probe a wider area of tissue in accordance with
the relation (l = (2DΔ)1/2) between the diffusion distance (l) and the dif-
fusion time (Δ). As a consequence, we hypothesize that the diffusion
signal at extended Δ will be more sensitive to the small changes in cell
density that are characteristic of the slow infiltration of gliomas. This
feature is well modelled in the investigated xenografts.
Currently, diffusion‐weighted imaging (DWI)26 and diffusion ten-
sor imaging (DTI)27,28 techniques are commonly used to investigate
diffuse infiltrative gliomas in both preclinical29,30 and clinical
settings.31,32 These techniques allow the detection of the invasive
pathways of glioma cell migration in the brain, which seem to
preferentially occur along the myelinated fibres in white matter
tracts.1,33Using optimized diffusion protocols at 14.1 T, the aim of this study
was to identify slow‐growing glioma sphere xenografts in their early
stages of growth, which are otherwise not visible using conventional
Gd‐DTPA enhanced T1‐weighted
34 and T2‐weighted MRI. In addition,
differences in diffusion indices of LN‐2669GS and LN‐2540GS glioma
sphere xenografts allowed the evaluation of differences in their
microstructure. Tumour growth detected by diffusion methods was
confirmed by localized proton MRS and immunohistochemistry.2 | MATERIALS AND METHODS
2.1 | Glioma‐derived sphere lines
Two human glioma‐derived sphere lines, LN‐2540GS and LN‐
2669GS,35,36 were used for orthotopic xenografts in nude mice. As
previously described,36 each line was derived by mechanical and
enzymatic dissociations of GBM surgical specimens into a single cell
suspension. After a CD133 (Miltenyi Biotec, Bergisch Gladbach,
Germany) selection procedure, cells were cultured under stem cell
conditions in DMEM‐F12 medium (Invitrogen, Carlsbad, CA, USA;
10565–018) supplemented with 2% of B27 (Invitrogen; 17504),
human recombinant epidermal growth factor (20 ng/ml) and human
recombinant basic fibroblast growth factor (20 ng/ml) (PeproTech,
Rocky Hill, NJ, USA; AF‐100‐15 and 100‐18B).
Basic genetic characterization and authentication have been pub-
lished previously.35,362.2 | Animal model
Orthotopic human gliomas were induced in eight female athymic nude
mice (Swiss nu/nu; Charles River Laboratories France, L'Arbresle,
France), aged 6–9 weeks and weighing 20–28 g. All experimental pro-
cedures and animal care were performed according to the federal and
local ethical guidelines and approved by the local veterinary authorities
(VD 1181–5). Mice were anesthetized and placed into a stereotaxic
frame (Stoelting, Wood Dale, IL, USA). Glioma sphere cells (1 × 105),
dissociated into a single cell suspension, were injected in a volume of
5 μl of PBS via a stereotaxic injector at a flow rate of 5 μl/min
(Quintessential Stereotaxic Injector (QSI)™, Stoelting) into the right
striatum of the mice (coordinates from bregma: 0.0 mm posterior,
2.5 mm lateral, 3.0 mm ventral; n = 4 per sphere line).2.3 | Animal preparation for MRI
Mice underwent MRI for the first time 50 days after orthotopic
implantation of human glioma sphere cells and then once a week. Con-
trol mice (n = 4) were also investigated using the same MRI protocol.
For MRI measurements, each mouse was anaesthetized with
isoflurane (4% induction, 1.5–2% maintenance) in a mixture of air:O2
(1:0.5 l/min induction, 0.7:0.3 l/min maintenance), and placed in a
home‐built dedicated holder with the head stereotaxically fixed by
ear pins and bite bar. Physiological monitoring was performed using
an MRI‐compatible small animal monitoring and gating system (Model
1025, SA Instruments, Stony Brook, NY, USA). The body temperature
was maintained in the range 36.5–37.5°C using a circulating warm
PORCARI ET AL. 1579water system, and the respiratory rate kept between 60 and 90 bpm
by regulating the isoflurane level.2.4 | MRI
All measurements were performed on a 14.1 T/26 cm horizontal bore
magnet (Magnex Scientific, Oxford, UK) interfaced to a Direct Drive
console (Varian Medical System, Palo Alto, CA, USA), and equipped
with a 12 cm inner diameter actively shielded gradient set (400 mT/
m in 120 μs). A two‐loop quadrature surface coil was used as an RF
transceiver for MRI and MRS. MRI protocol included T2‐weighted
images, DWI and DTI scans. After measuring scout scans, multi‐slice
T2‐weighted fast spin‐echo images of mouse brain were acquired in
the coronal orientation as an anatomical reference (TR/Teff = 5000/
52 ms, echo train length = 8, field of view =20 × 20 mm2, matrix size
=256 × 256, in‐plane resolution =78 × 78 μm2, 13 slices of 0.6 mm
thickness, four averages, scan time = 10 min). Static field homogeneity
was optimized by adjusting all first and second order shims using an
EPI version of FASTMAP (fast automatic shimming techniques by map-
ping along projections),37 resulting in water linewidths of 18–24 Hz
over the selected volume of interest (VOI; 6 × 5 × 4.5 mm3) centred
in the mouse brain.
Diffusion‐weighted images of mouse brain were acquired in the
coronal orientation using a pulse gradient stimulated echo (PGSTE)
sequence38 (TR/TE = 4000/22 ms; field of view =20 × 10 mm
2, matrix
size =128 × 64, in‐plane resolution =156 × 156 μm2, eight slices of
1 mm thickness sufficient to cover the whole tumour and the
peritumoral areas, two averages, scan time = 67 min).
To optimize DWI and DTI protocol for glioma detection, a pilot
study was carried out on mice with LN‐2540GS xenograft at early
stages of tumour development by exploring several diffusion times
(Δ = 40, 60, 80, 100, 150, 220 ms) with gradient duration (δ) equal to
4 ms. For each Δ, DWI data were acquired using eight b values (294,
389, 542, 754, 1024, 1352, 2185, 2688 s/mm2) with the diffusion gra-
dient applied along the readout direction (X axis). The corresponding
gradient amplitudes are summarized in Table 1. It is of note that the
calculation of b values includes the contribution of imaging and crusher
gradients, which lead to b0 values for the unweighted diffusion images,
as reported in Table 1. The contrast‐to‐noise ratio (CNR) of the tumour
was calculated for each diffusion‐weighted image (acquired at eachTABLE 1 DWI protocol used to optimize tumour visualization. Summary o
diffusion time (Δ) used in the DWI acquisition
b
values
[s/mm2] Δ = 40 ms Δ = 60 ms Δ = 80 ms
294 4.6 2.0 0.0
389 6.0 3.6 1.8
542 7.8 5.4 3.6
754 9.7 7.3 5.4
1024 11.9 9.4 7.2
1352 14.0 11.4 9.0
2185 19.1 15.8 12.6
2688 21.3 17.4 14.4
A missing value (—) means a b0 value higher than the considered b values (b0 =specified Δ and b value) as the difference between the mean signal
from regions of interest (ROIs) drawn (as circular areas of the same
size) in the contralateral area, 〈CL〉, and in the tumour, 〈T〉, divided by
the standard deviation of the signal in the CL region, σ(CL),
[CNR = (〈CL〉 − 〈T〉)/σ(CL)] (Table 2). The signal‐to‐noise ratio (SNR)
of tumour was determined for each Δ on the b0 image as the mean
signal intensity of a ROI drawn in the tumour location (〈T〉) divided
by the standard deviation (σ) of a large ROI in the background noise
(N), that was visually devoid of artefacts (SNR = 〈T〉/σ(N)).
Following the observation in this pilot study, the main DWI proto-
col for both glioma sphere‐derived xenografts, LN‐2669GS and LN‐
2540GS, used Δ = 80 ms with all the above‐specified b values, which
was justified by the pilot study CNR data (Table 2, Figure 1). The same
DWI protocol was also carried out with diffusion gradients applied
along the phase encoding (Y‐axis) and the slice selection (Z‐axis)
directions.
CNR of tumour growing from both glioma sphere xenografts was
also determined for Δ = 80 ms as a function of b values for the DWI
data acquired during the last MRI session.
DTI data were collected by acquiring seven images, one b0 image
(no diffusion weighting, b = 0 s/mm2) and six diffusion‐weighted
images, each of them with the same b value of 1352 s/mm2 (which
was found to provide the best tumour contrast by exploring different
Δ and b values in DWI scans as shown in Table 2) and encoding gradi-
ents applied in six unique orientations ([1, 0, 0], [0, 1, 0], [0, 0, 1], [1/
√2 , 1/√2, 0], [1/√2, 0, 1/√2], [0, 1/√2, 1/√2]). The acquisition time
was 58 min.
Apparent diffusion coefficient (ADC) maps of mouse brain were
computed by fitting, voxel by voxel, the signal intensity of the diffu-
sion‐weighted images as a function of b values (S(b) = S(0) exp(−b
ADC)).
Diffusion tensor maps, mean diffusivity (MD) and fractional
anisotropy (FA), which reflect respectively the average diffusivity and
the degree of anisotropy in each voxel,27 were computed by
reconstructing the tensor. All diffusion maps, ADC, MD and FA, were
computed using the FSL DTIFIT routine (FSL, Version 4 software;
http://www.fmrib.ox.ac.uk/fsl).
ROIs containing the tumour, a CL area and the corresponding
brain regions of controls were drawn (as circular areas of the same size)
on the ADC,MD and FAmaps with reference to the diffusion‐weightedf diffusion gradient amplitudes (G) corresponding to each b value and
G [G/cm]
Δ = 100 ms Δ = 150 ms Δ = 220 ms
— — —
0.2 — —
2.3 — —
4.1 1.6 —
5.9 3.5 1.3
7.5 4.6 2.4
10.4 7.8 5.0
12.2 9.0 5.8
381, 590 and 884 s/mm2 for Δ = 100, 150 and 220 ms, respectively).
TABLE 2 Summary of CNR determined from DW images acquired with different Δ and b‐values from mouse brain with slow growing and highly
infiltrative tumour at early stage of growth
b values
[s/mm2]
CNR
Δ = 40 ms Δ = 60 ms Δ = 80 ms Δ = 100 ms Δ = 150 ms Δ = 220 ms
294 −0.43 ± 0.08 0.16 ± 0.04 0.54 ± 0.10 — — —
389 0.53 ± 0.02 0.87 ± 0.04 1.01 ± 0.15 0.88 ± 0.09 — —
542 0.52 ± 0.04 0.94 ± 0.12 1.61 ± 0.08 1.46 ± 0.12 — —
752 1.22 ± 0.07 1.44 ± 0.09 1.63 ± 0.09 1.66 ± 0.06 1.44 ± 0.04 —
1024 1.34 ± 0.09 1.72 ± 0.06 2.05 ± 0.07 1.89 ± 0.05 1.55 ± 0.08 1.31 ± 0.08
1352 1.51 ± 0.12 1.84 ± 0.10 2.36 ± 0.12 2.04 ± 0.11 1.83 ± 0.13 1.47 ± 0.12
2185 0.98 ± 0.09 1.43 ± 0.09 1.98 ± 0.10 1.24 ± 0.23 1.01 ± 0.09 0.86 ± 0.25
2688 0.71 ± 0.10 1.01 ± 0.08 1.44 ± 0.09 0.80 ± 0.16 0.37 ± 0.09 −0.16 ± 0.03
All values are mean ± SD.
A missing value (—) indicates no DW images were available for the evaluation of the CNR.
FIGURE 1 In vivoMRI of LN‐2540GS glioma sphere xenograft, 80 days after cell injection (pilot study data). Diffusion‐weighted images of a mouse
brain with LN‐2540GS glioma sphere xenograft acquired with different diffusion times (Δ = 40, 60, 80, 100, 150, 220 ms) and the same b value
(1352 s/mm2). C shows a slightly better tumour contrast compared with the others
1580 PORCARI ET AL.image with Δ = 80 ms, b = 1352 s/mm2, where tumour showed better
contrast (Table 2). The CL area was selected considering the brain
region symmetric to the tumour location with respect to the mid‐
sagittal plane. Mean values of ADC, MD and FA were calculated in
the selected ROIs using a custom MATLAB script.
Statistically significant difference between the mean values of dif-
fusion indices calculated in the selected ROIs of all tumour slices in all
mice and in the corresponding CL was accepted for P < 0.05, as deter-
mined with a two‐tailed, paired Student's t test. Comparison between
the diffusion indices calculated in the tumour of both xenografts as
well as the comparison between the diffusion indices calculated in
the tumour of each xenograft and in the corresponding brain region
of the control group were considered as statistically significant for
P < 0.05, as determined with a two‐tailed, unpaired Student's t test.
2.5 | MRS
Spectra of gliomas were acquired during the final MRI session in each
mouse. Proton spectra were collected using a short echo‐time
(TE = 2.8 ms) spin echo, full intensity acquired localized (SPECIAL)
39
spectroscopy sequence from a VOI (2 × 2 × 2 mm3) located within
the tumour, based on coronal diffusion‐weighted images. Beforemeasurements, field homogeneity was adjusted in the selected VOI,
as mentioned above. Outer volume suppression interleaved with a
VAPOR (variable power and optimized relaxation delays)40 water sig-
nal suppression was used. Spectra were acquired with TR = 4000 ms,
15 blocks of 16 transients (total scan time 16 min), spectral width of
7 kHz and 4096 data points. Each block was corrected for static field
drift and summed for further analysis. Spectra from brain regions of
healthy mice matching tumour size and location in the brain of injected
mice were acquired for comparison.
Metabolite concentrations were quantified using LCModel41 and
absolute concentrations of metabolites were calculated using an
unsuppressed water peak as a reference.
Statistically significant levels were accepted for P < 0.05, as
determined with a two‐way ANOVA followed by the Bonferroni
multi‐comparison post‐tests.
2.6 | Immunohistochemistry
All mice were sacrificed approximately 5 months after implantation,
when gliomas were sufficiently large (maximum dimension of
2–3 mm) in diffusion‐weighted images. Brains were dissected, fixed
in formalin (4% buffered formalin) and embedded in paraffin. Tissue
PORCARI ET AL. 1581sections (5 μm) were stained with H&E (haematoxylin and eosin) or
immunostained for the proteins GFAP (glial fibrillary acidic protein;
G3893, Sigma‐Aldrich, St. Louis, MO, USA), mindbomb E3 ubiquitin
protein ligase 1 (MIB‐1; monoclonal antibody (MAB), M7240, Dako,
Glostrup, Denmark), p53 (MAB, Dako, M7001),36 using standard pro-
cedures (Ventana Medical System, Tucson, AZ, USA), and human
nucleolin (hNCL, 1:200, 4°C, overnight; ab13541, Abcam, Cambridge,
UK; does not react with mouse). For hNCL, the antigen retrieval pro-
cedure in citrate phosphate buffer (pH 6.0) was performed at 95°C
for 60 min followed by 8 min at 120°C (pressure cooker), and an
additional blocking step of 15 min with Rodent Block M (catalogue
no RBM 961, Biocare Medical, Concorde, CA, USA) was added to
the standard procedure. Immunoreactivity was visualized using
DAB (diaminobenzidine tetrahydrochloride).3 | RESULTS
3.1 | MRI results
The diffusion time Δ = 80 ms was found to be optimal for identifying
the glioma sphere xenografts, as shown from the pilot study CNR data
(Table 2, Figure 1). The extension of the lesions was not properly
visualized using lower diffusion times, whereas higher Δ led to
unacceptably low SNR.
Tumours grown as LN‐2669GS and LN‐2540GS glioma sphere
xenografts in mouse brain were detected for the first time three
months after glioma implantation, as shown in Figure 2 and Figure 3,
respectively. Each of the figures shows typical T2‐weighted and
diffusion‐weighted images (Figure 2A,B and Figure 3A,B) acquired
three months after cell injection and the calculated ADC, and DTI maps
(Figure 2C–F, Figure 3C–F) of a coronal slice from the mouse brain
with LN‐2669GS NCH‐1364 and LN‐2540GS NCH‐1365 glioma
sphere xenograft, respectively.
In both figures, the hypo‐intense region on the diffusion‐weighted
images (Figures 2B, 3B), which is just visible for the LN‐2669GS
NCH‐1364 xenograft (Figure 2B), and the corresponding hyper‐FIGURE 2 In vivo MRI of LN‐2669GS glioma sphere xenograft, three mon
sion‐weighted (B) images of the mouse brain with LN‐2669GS xenograft NC
diffusion tensor maps, MD (D), FA (E), and FA‐modulated directionally enc
diffusion‐weighted image (B), ADC (C) and DTI mapsintense area on the ADC and MD maps (Figure 2C,D, Figure 3C,D) as
well as the hypo‐intense region on the FA map (Figure 2E, Figure 3E),
shows the extent of the tumour. In contrast, no lesion is visible in the
T2‐weighted images (Figure 2A, Figure 3A).
Figure 4 and Figure 5 show coronal T2‐weighted and diffusion‐
weighted images (Figure 4A,B and Figure 5A,B) acquired five months
after injection of the cells as well as the computed ADC and DTI maps
(Figure 4C–F, Figure 5 C–F) from the mouse brain of the same mice as
displayed in Figure 2 and Figure 3, respectively. As with Figure 2 and
Figure 3, both xenografts are visible in the diffusion‐weighted
images (Figure 4B, Figure 5B) as well as in the ADC (Figure 4C,
Figure 5C) and DTI maps (Figure 4D–F, Figure 5D–F), whereas no
evidence of tumour is seen in the corresponding T2‐weighted
image (Figure 4A, Figure 5A).
Compared with Figure 2 and Figure 3, tumours grown from both
sphere lines are more visible in Figure 4 and Figure 5 at five months
after cell injection, due to tumour development.
Figure 6 shows DWI acquisition on the mouse brain comprising
the LN‐2540GS xenograft NCH‐1365 (A) as well as the CNR data for
both xenografts (B). All data were acquired during the last MRI session.
The progression of diffusion‐weighted images (Figure 6A, a–h),
acquired two weeks after those presented in Figure 5, demonstrates
an improved delineation of tumour margins when the b value
increases. In particular, the lesion becomes visible when b is higher than
500 s/mm2 (Figure 6A, c), and the higher the b value themore noticeable
the tumour (Figure 6A, c–h), which appears as a hypo‐intense lesion
on the diffusion‐weighted images (Figure 6A, c–h) and as a hyper‐
intense area in the corresponding ADC map (Figure 6A, k). Conversely,
the lesion is not visible on the T2‐weighted image (Figure 6A, j) that
shows only a ventricular enlargement, as in Figure 5A.
The CNR data shown in Figure 6B are displayed as a function of b
values (Δ = 80 ms) for images acquired in the last MRI session (Figure 4
and Figure 6A). The best tumour contrast is given for both xenografts
at a b value equal to 1352 s/mm2, the same as given by the pilot study
CNR data (Table 2).
Mean values of the diffusion indices calculated in the tumour (T)
and in the corresponding contralateral (CL) area of each xenograft asths after cell injection. Upper panel: coronal T2‐weighted (A) and diffu-
H‐1364, and the calculated ADC map (C). Lower panel: corresponding
oded colour (DEC) (F) maps. The lesion (arrow) is barely visible on the
FIGURE 3 In vivoMRI of LN‐2540GS glioma sphere xenograft, three months after injection of the cells. Upper panel: coronal T2‐weighted (A) and
diffusion‐weighted (B) images of the mouse brain with LN‐2540GS xenograft NCH‐1365, and the calculated ADC map (C). Lower panel: corre-
sponding diffusion tensor maps, MD (D), FA (E) and FA‐modulated DEC (F) maps. The lesion (arrow) is visible on the diffusion‐weighted image (B),
ADC (C) and DTI maps
FIGURE 4 In vivo MRI of LN‐2669GS glioma sphere xenograft, five months after injection of the cells. Upper panel: coronal T2‐weighted (A) and
diffusion‐weighted (B) images of the mouse brain with LN‐2669GS xenograft NCH‐1364, and the calculated ADC map (C). Lower panel: corre-
sponding diffusion tensor maps, MD (D), FA (E) and FA‐modulated DEC (F) maps. The lesion (arrow) is visible on the diffusion‐weighted image (B)
and ADC (C) and DTI maps. Due to the highly invasive and diffuse character of this tumour (corresponding histology, Figure 9A) it is difficult to
delineate tumour borders
FIGURE 5 In vivo MRI of LN‐2540GS glioma sphere xenograft, five months after injection of the cells. T2‐weighted (A) and diffusion‐weighted (B)
images, and the calculated ADC map (C); MD (D), FA (E) and FA‐modulated DEC (F) maps of a coronal slice from the mouse brain with the
LN‐2540GS xenograft NCH‐1365. MD, FA and DEC maps, computed after DTI reconstruction, show a lesion (indicated by the arrow)
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FIGURE 6 In vivo MRI of LN‐2540GS glioma sphere xenograft (A) and CNR data of both xenografts (B), all acquired during the last MRI session
(five months after injection of the cells). A, Left panel: coronal diffusion‐weighted images (a–h) of the mouse brain with LN‐2540GS xenograft
NCH‐1365. Images are related to the DWI acquisition with b values increasing along the readout direction. Right panel: corresponding anatomical
T2‐weighted image (j) and ADC map (k) of glioma‐bearing xenograft. Images were acquired 15 days after those shown in Figure 5. A lesion (indi-
cated by arrow and delineated by a dotted line in (g)) is visible on the diffusion‐weighted images (c–h) and the ADC map. B, The CNR data of LN‐
2669GS xenograft NCH‐1364 and LN‐2540GS xenograft NCH‐1365 as a function of b values obtained in the last MRI session
PORCARI ET AL. 1583well as in the same brain regions of controls are summarized in Table 3
and Table 4 for both xenografts at early stages of tumour development
(three months after injection) and at five months after cell injection,
respectively.
For both stages of tumour growth, either three months or five
months after cell injection (Table 3 and Table 4, respectively), a signif-
icant increase in MD was observed in tumours grown as LN‐2669GS
xenografts compared with those grown from LN‐2540GS cells, with
the CL area and with the values obtained from the same brain regions
of controls. On the other hand, a significant decrease in FA was
observed in both cases (Table 3 and Table 4) in tumours grown as
LN‐2669GS xenograft, whereas no changes were observed in those
grown from LN‐2540GS cells compared with the CL area and the con-
trol. Moreover, ADC values increased similarly in tumours grown fromeach xenograft (LN‐2669GS or LN‐2540GS xenografts), either at three
or five months after cell injection (Table 3 and Table 4, respectively),
compared with those in the contralateral area and in the controls.
By comparing the corresponding values of the diffusion indices for
each stage of tumour development, either three months (Table 3) or
five months after cell injection (Table 4), the diffusion indices are
slightly lower at earlier stages of tumour growth (Table 3). However,
no significant difference was found between each corresponding diffu-
sion indices in the two investigated stages of tumour development.3.2 | MRS results
Proton spectra were measured immediately before sacrificing mice for
histological assessment. In Figure 7, 1H spectra of a mouse brain from a
TABLE 4 Summary of ADC values, FA and MD indices of tumour (T) and contralateral (CL) area of both LN‐2669GS and LN‐2540GS xenografts at
5 months after cell injection. ADC values and DTI indices obtained from the corresponding brain regions of the control group are also reported.
Data are mean ± s.e.m.
LN‐2669GS xenograft LN‐2540GS xenograft
ControlaT CL T CL
ADC [10−3 mm2/s] 0.67 ± 0.07b,c 0.53 ± 0.07 0.65 ± 0.04b,c 0.54 ± 0.05 0.54 ± 0.02
FA 0.16 ± 0.02b,c,d 0.19 ± 0.02 0.20 ± 0.03 0.19 ± 0.02 0.19 ± 0.02
MD [10−3 mm2/s] 0.71 ± 0.04b,c,d 0.57 ± 0.04 0.66 ± 0.05b,c 0.56 ± 0.03 0.57 ± 0.03
aControl data were computed from regions corresponding to tumour location, symmetrically in both hemispheres.
Statistics:
bsignificantly different from CL area in the same group (paired two‐tailed t test, p < 0.01);
csignificantly different from the related brain regions in the controls (unpaired two‐tailed t test, p < 0.01),
dsignificantly different from the corresponding value in tumour grown as LN‐2540GS xenograft.
TABLE 3 Summary of ADC values, FA and MD indices of tumour (T) and contralateral (CL) areas of both LN‐2669GS and LN‐2540GS xenografts
at early stages of tumour development (3 months after cell injection). ADC values and DTI indices obtained from the corresponding brain regions of
the control group are also reported. Data are mean ± s.e.m.
LN‐2669GS xenograft LN‐2540GS xenograft
ControlaT CL T CL
ADC [10−3 mm2/s] 0.65 ± 0.04b,c 0.53 ± 0.06 0.64 ± 0.02b,c 0.54 ± 0.05 0.56 ± 0.02
FA 0.15 ± 0.03d 0.18 ± 0.04 0.19 ± 0.03 0.18 ± 0.03 0.18 ± 0.05
MD [10−3 mm2/s] 0.69 ± 0.07b,c, d 0.58 ± 0.05 0.64 ± 0.05b,c 0.58 ± 0.03 0.58 ± 0.03
aControl data were computed from regions corresponding to tumour location, symmetrically in both hemispheres.
Statistics:
bsignificantly different from CL area in the same group (paired two‐tailed t test, p < 0.01);
csignificantly different from the related brain regions in the controls (unpaired two‐tailed t test, p < 0.01),
dsignificantly different from the corresponding value in tumour grown as LN‐2540GS xenograft.
1584 PORCARI ET AL.control (Figure 7A), LN‐2669GS xenograft NCH‐1364 (Figure 7B) and
LN‐2540GS xenograft NCH‐1365 (Figure 7C) are shown.
The spectra of tumours (Figure 7B,C) were acquired 5 months
after injection of glioma sphere cells and compared with the control
spectrum (Figure 7A). The main changes in metabolite concentrations
(indicated by arrows) are depicted in Figure 7 and Figure 8.
In particular, the tumour grown from the LN‐2669GS sphere line
(Figure 7B) showed a decrease in N‐acetylaspartate (NAA; 4.7 μmol/
g versus 7.7 ± 0.4 μmol/g in controls, p < 0.01), glutamate
(Glu; 4.7 μmol/g versus 8.4 ± 0.4 μmol/g, p < 0.001), NAA + N‐
acetylaspartylglutamate (NAAG) (5.7 μmol/g versus 8.6 ± 0.4 μmol/g,
p < 0.01) and Glu + glutamine (Gln) (8.2 μmol/g versus
10.8 ± 0.4 μmol/g, p < 0.05) concentrations, and an increase in myo‐
inositol (Ins; 10.8 μmol/g versus 4.3 ± 0.4 μmol/g, p < 0.0001) and glu-
cose (Glc) (4.7 μmol/g versus 1.5 ± 0.3 μmol/g, p < 0.01) ones (solid
black bars, Figure 8).
The tumour grown from the LN‐2540GS sphere line (Figure 7C)
showed a more profound reduction in NAA (1.8 μmol/g versus
7.7 ± 0.4 μmol/g in controls, p < 0.0001), Glu (3.7 μmol/g versus
8.4 ± 0.4 μmol/g, p < 0.0001), NAA + NAAG (2.6 μmol/g versus
8.6 ± 0.4 μmol/g, p < 0.0001) and Glu + Gln (6.2 μmol/g versus
10.8 ± 0.4 μmol/g, p < 0.0001) concentrations and an increase in the
Ins (15.0 μmol/g versus 4.3 ± 0.4 μmol/g, p < 0.0001) and Glc
(6.4 μmol/g versus 1.5 ± 0.3 μmol/g, p < 0.0001), with additional
changes in glycine (Gly; 5.0 μmol/g versus 1.2 ± 0.1 μmol/g,
p < 0.001) and taurine (Tau; 5.7 μmol/g versus 12.6 ± 1.1 μmol/g,p < 0.0001), when compared with the LN‐2669GS sphere line (solid
grey bars, Figure 8).3.3 | Immunohistochemical results
In order to assess imaging and spectroscopic results, histological and
immunohistochemical analysis was performed on each mouse. Due to
the highly invasive nature of the human LN‐2669GS cells, the intrace-
rebral lesion was not visible on the H&E section (Figure 9a). The hNCL
immunostaining (Figure 9c,d) identifies the human tumour cells, and
visualizes the infiltrative growth pattern of the human LN‐2669GS
tumour cells. GFAP expression indicated a region with enhanced gliosis
that reached over to the co‐lateral side, probably induced by tumour
cell infiltration (Figure 9b). The area with strongest gliosis, as indicated
by GFAP expression, shown in Figure 9b, correlates with the hypo‐
intense region in the diffusion‐weighted image (Figure 4B), the hyper‐
intense areas in the ADC and MD maps (Figure 4C,D) and the
hypo‐intense regions in the FA map (Figure 4E). Images shown in
Figure 4 aswell as the spectrumdisplayed in Figure 7Bwere all acquired
during the last MRI session, immediately before euthanizing the mouse.
The LN‐2540GS xenograft comprises a compact and a more inva-
sive component visualized on the H&E (Figure 9e) and the GFAP
immunostained (Figure 9f) coronal section as well as by the nuclear
expression of tumour protein 53 (TP53; not shown), which is detected
in all tumour cells, in agreement with hNCL staining (Figure 9g). The
high cell density in the compact tumour area is visualized in Figure 9h.
FIGURE 7 1H spectra of the brain from a control mouse (A) and from a tumour derived from LN‐2669GS xenograft NCH‐1364 (B), and a tumour
derived from LN‐2540GS xenograft NCH‐1365 (C). Spectra B and C were acquired 5 months after cell injection. Spectra are displayed with a
Gaussian filter (0.11)
PORCARI ET AL. 1585The tumour area visible in Figure 9e–g correlates with the hypo‐
intense regions visible on the DWI acquisition (Figure 6c–h) and the
hyper‐intense area shown in Figure 6k. Images shown in Figure 6A
and the spectrum reported in Figure 7C were all acquired during the
last MRI session, immediately before the mice were euthanized.
It is of note that the two xenografts display a striking difference in
cell density, as visualized in Figure 9d,h, displaying at high magnifica-
tion an area of human tumour cells (with the same magnification):
the LN‐2669GS xenograft (Figure 9A, d) shows a lower tumour cell
density than the LN‐2540GS xenograft (Figure 9B, h).In addition, none of the histological sections of both xenografts
shows any areas of necrosis, in accordance with imaging results.4 | DISCUSSION
We have developed a diffusion MR protocol at 14.1 T for early
detection and investigation of human glioma xenografts in mice.
Its performance was documented on human glioma xenografts
derived from the sphere lines LN‐2540GS and LN‐2669GS,
FIGURE 8 Absolute metabolite concentrations in the tumours grown from LN‐2669GS and LN‐2450GS sphere lines as well as in the same brain
region of control mice obtained by in vivo MR spectroscopy 5 months after injection of the cells. Statistic: *Absolute metabolite concentrations
from tumour grown from LN‐2669GS NCH‐1364 significantly different from those of the same brain region of controls (p < 0.05); **p < 0.01;
***p < 0.001; ****p < 0.0001; †††absolute metabolite concentrations from tumour grown from LN‐2540GS NCH‐1365 significantly different from
those of the same brain region of controls (p < 0.001); ††††p < 0.0001
FIGURE 9 Histology of the LN‐2669GS and LN‐2540GS derived xenografts. For both xenografts full brain sections are shown for H&E stain (a,e),
and immunohistochemistry for GFAP (b,f), and the human specific NCL protein (c,d,g,h). A, In the LN‐2669GS xenograft (NCH‐1364), the H&E
stained section (a) does not reveal the lesion, with the exception of a small compact tumour part at the surface of the brain due to reflux at the
injection site. The GFAP (b) expression (arrow) indicates gliosis induced by infiltrating tumour cells. The visualization of the human tumour cells by
hNCL (c,d) indicates the highly invasive growth properties of the LN‐2669GS xenograft NCH‐1364 (magnification of themarked area (*), scale bar 10
μm). B, The LN‐2540GS xenograft is readily visible with H&E, identifying a compact and an invasive part (e). Magnification of the marked area (*) in
the hNCL immunostained section (h) indicates high cell density in the most compact part of the LN‐2540GS xenograft NCH‐1365 (scale bar 10 μm)
1586 PORCARI ET AL.characterized by their slow and diffuse infiltrative growth in the
mouse brain.8 With the optimized acquisition parameters of the
diffusion‐weighted stimulated‐echo (PGSTE) sequence, in particular
the diffusion time (Δ = 80 ms), the protocol allowed a proper
detection and investigation of both xenograft models in the regime
of hindered diffusion.
Different diffusion times (Δ = 40–220 ms) were explored in a pilot
study carried out on LN‐2540GS glioma sphere xenografts at early
stages of growth, and the best tumour contrast was found for
Δ = 80 ms (Table 2). By selecting this observation time, the diffusion
distance (l ~ 10 μm) was comparable to the average distance
between glioma sphere cells, which were not densely packed
within the investigated xenografts due to their diffuse infiltrative
growth. Therefore, shorter Δ does not give a proper tumour
contrast, whereas Δ = 80 ms, by probing the distance between gli-
oma sphere cells, optimizes tumour contrast for the investigated
xenografts.Different diffusion properties due to diverse tumour microstruc-
ture in each model were also demonstrated by the calculated diffusion
indices. Finally, the presence of tumours was confirmed by localized
spectroscopy and by immunohistochemical analysis, which also
provided information on morphologic tumour properties.
As it is well known38 the advantage of the PGSTE sequence is the
use of long diffusion times, avoiding signal loss due to the transverse
relaxation time T2. On the other hand, its main disadvantage is a loss
of 50% of the MR signal.42 We partly compensated this loss by using
the shortest possible TE (22 ms), an ultra‐high magnetic field and a
small surface coil (dimensions of 21 mm × 14 mm). However, the
increase in SNR due to the high magnetic field was reduced by shorter
transverse relaxation time T2. In addition, larger susceptibility effects
due to the high magnetic field made the detection of glioma sphere
xenografts even more challenging.
Tumours grown in both xenograft models were not visible on
T2‐weighted images (Figures 2A, 3A, 4A, 5A and 6j), even though
PORCARI ET AL. 1587a ventricular enlargement indicating tumour presence was observed
on the T2‐weighted image (Figure 6) of the mouse brain with the
LN‐2540GS xenograft. Detection of slow‐growing tumours from
glioma‐initiating cells was also difficult using contrast‐enhanced
T1‐weighted MRI.
34
During investigation of glioma sphere xenografts by means of
diffusion MRI, the first evidence of tumour presence on diffusion‐
weighted images was revealed three months after glioma sphere
cell injection for both xenograft models (Figure 2 and Figure 3).
The absence of signs of necrosis and haemorrhagic foci in MR
images, which was confirmed by histology, underlined the problem-
atic detection of these slowly growing tumours using standard MRI
techniques.
Different diffusion properties between glioma xenografts grown
from LN‐2669GS and LN‐2540GS, respectively, were observed at
three months (Table 3) and five months after cell injection (Table 4).
At both time points, the larger MD in the LN‐2669GS tumour
model indicates that water molecules diffuse faster in tumours
grown as LN‐2669GS xenografts than in those grown from
LN‐2540GS cells that, in addition to the infiltrative part, comprise a
compact tumour component. Faster diffusion behaviour in the
tumour grown from LN‐2669GS compared with LN‐2540GS is
probably explained by the much lower cell density of the former
(Figure 9d,h). Moreover, the reduced FA in the LN‐2669GS model sug-
gests loss of anisotropy in this tumour compared with the one grown
from LN‐2540GS cells, indicating a looser and less anisotropic tumour
microstructure in the LN‐2669GS engraft, which is also in accor-
dance with histology. However, the six gradient orientations used
in this study, as described in the method section, do not provide
an optimal sampling scheme for obtaining detailed information from
the FA maps.
The growth properties of the glioma sphere cell line‐derived xeno-
grafts in this study were highly invasive, without formation of central
necrosis. These properties allowed the investigation of invasive
tumour characteristics, which are a major diagnostic problem in
patients with GBM and low grade gliomas, to determine the extent
of the tumour requiring treatment. Thus, our imaging results suggest
that diffusion techniques can be more successful than standard
T2‐weighted MR images in detecting infiltrative tumours growing
slowly as xenografts in mouse brain.
The comparison between 1H spectra of the two investigated
xenograft models shows more pronounced changes in absolute
metabolite concentrations in tumours derived from LN‐2540GS than
in those from the LN‐2669GS sphere line (Figure 7 and Figure 8). This
may be explained by different characteristics of these tumours. Since
spectra of both xenografts were measured at the same time point
after cell injection (5 months), the spectral profile of tumours grown
from LN‐2540GS sphere line may indicate faster growing tumours
compared with those grown as LN‐2669GS xenograft. The diffusion
results support this finding, as shown by comparing MR images
between the two xenografts at three months (Figure 2 and
Figure 3, respectively) and five months after cell injection (Figure 4
and Figure 5). Moreover, the faster growing tumours, LN‐2540GS
xenografts, are characterized by a lower MD compared with that
of LN‐2669GS xenografts. This is consistent with a more compacttumour for the LN‐2540GS xenograft compared with that grown
from LN‐2669GS sphere lines, which is in accordance with tumour
histology.5 | CONCLUSION
In vivo measurements performed in this study showed that the diffu-
sion MRI technique is a useful method to detect and follow slowly
growing, diffuse infiltrative tumours in the mouse brain. Imaging data
in combination with localized proton spectra of lesions and immuno-
histochemical assessment demonstrated that the optimized diffusion
MRI protocol can be useful in early detection of slow‐growing human
glioma xenografts as well as in the investigation of diffusion properties
of tumours during their growth. Moreover, the calculated diffusion
indices in the tumours reflected microstructural differences between
LN‐2669GS and LN‐2540GS xenografts, confirmed by histology. The
diffusion parameters measured at a moderately long diffusion time
(i.e. Δ = 80 ms) can be considered as potential biomarkers for early
detection of diffuse infiltrative gliomas in humans due to the possible
implementation of the proposed protocol on the clinical MR scanners.ACKNOWLEDGEMENTS
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